Atom Bioscience and Pharmaceutical

Company Deals

Atom Bioscience Secures $82M Series D to Advance Gout Treatment ABP-671

Fineline Cube Oct 16, 2023

China-based Atom Bioscience, known formally as Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd, has reportedly...

Company Drug

Atom Bioscience Initiates Global Phase III Clinical Study for Gout Drug ABP-671

Fineline Cube Oct 10, 2023

China-based Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd) has announced the enrollment of...

Company Drug

Atom Bioscience’s ABP-671 Shows Positive Phase IIa Results in Gout Treatment

Fineline Cube Mar 3, 2023

China-based Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd) has announced positive results from...

Company

Fosun Pharma Reports 2025 Results – Innovative Drug Revenue Surges 30% to RMB 9.9 Billion, Overseas Sales Hit RMB 13 Billion

Company Drug

Alphamab Oncology Doses First Patient in Phase III KN026 Study – Bispecific HER2 Antibody Targets Adjuvant Breast Cancer

Others

Gilead to Acquire Ouro Medicines for $2.175 Billion – Keymed Biosciences Secures $320 Million from CM336 TCE Deal

Company Drug

Shenzhen Salubris Wins NMPA Approval for SAL0150 – Oral Long-Acting Diabetes/Obesity Drug Targets Weekly Dosing Regimen